TE-1 Orthotopic Mouse Model Service for Esophageal Cancer

Implanting TE-1 human esophageal squamous carcinoma cells directly into the esophageal wall, the TE-1 orthotopic mouse model reproduces the anatomy and tumor–stroma interactions of the primary disease, providing a rigorous preclinical setting for evaluating tumor progression and candidate therapies. With deep hands-on experience in orthotopic surgical modeling, Alfa Cytology stands ready to build, monitor, and analyze TE-1 orthotopic models according to each client's study design, from pilot experiments to full efficacy programs.

Overview of TE-1 Orthotopic Mouse Model for Esophageal Cancer

TE-1 holds a special place in esophageal cancer research as one of the earliest human esophageal squamous cell carcinoma (ESCC) cell lines ever established. Described in 1979 by Nishihira and co-workers from a tumor resected from a 58-year-old Japanese male patient, the line was among the first ESCC models available to laboratories worldwide and has since anchored thousands of in vitro and in vivo studies. TE-1 cells carry a characteristic TP53 mutation (p.Val272Met), and early biochemical work on the line famously revealed that human esophageal carcinoma cells express fewer but higher-affinity epidermal growth factor receptors than other tumor cell types — an observation that shaped thinking about growth factor signaling in this disease. Whole-transcriptome analyses have further mapped its gene expression landscape, highlighting altered MAPK signaling, metabolic rewiring, and adhesion pathways relative to normal esophageal cells.

Fig 1. Anlotinib exhibits anticancer activity in TE-1 tumor cell xenograft mice. (Liu, Yueli, et al., 2024)

In vivo, TE-1 is a dependable xenograft former in immunodeficient mice and is counted among the ESCC lines documented for orthotopic use. When TE-1 cells are implanted into the esophageal wall rather than the subcutaneous space, the resulting tumors grow within the native organ environment: they engage esophageal fibroblasts, smooth muscle, and vasculature, infiltrate the wall layers, and generate the mechanical and nutritional consequences of a true esophageal tumor. Orthotopic TE-series models have been reported to produce locally invasive growth with regional lymph node involvement and peritoneal dissemination under appropriate conditions, and body weight loss reflecting impaired food intake has been documented as a clinically relevant readout. These properties make the TE-1 orthotopic model a strong choice for investigating tumor–stroma crosstalk, testing anti-cancer agents under physiologically relevant conditions, and exploring strategies against radioresistance — a question for which the radiation-selected TE-1R derivative, enriched by fractionated irradiation (1 Gy × 3, 2 Gy × 3, and 4 Gy × 3), offers a matched resistant comparator.

Cell Line Information: TE-1

Few ESCC lines carry as much historical weight as TE-1, and its long record of use has produced an unusually complete body of characterizations. The principal features of the line are summarized below.

Our Services

Researchers choosing Alfa Cytology for TE-1 orthotopic modeling gain a partner that treats every stage — cell authentication, intramural implantation, in-life monitoring, and endpoint histopathology — as a quality-critical step, ensuring that the final dataset reflects the biology of esophageal cancer rather than procedural variability.

Workflow of TE-1 Orthotopic Mouse Model Construction

TE-1 orthotopic tumors are established through laparotomy-based intramural implantation, the most widely adopted technique for ESCC orthotopic modeling with this line. The procedure generally unfolds as follows.

1. Cell authentication and expansion: TE-1 cells are confirmed by STR profiling and mycoplasma testing, then expanded under standardized culture conditions and harvested in the exponential growth phase.
2. Inoculum preparation: Cells are counted and assessed for viability, then mixed with ice-cold Matrigel at a defined density — typically on the order of 1 × 10⁶ cells in 20–30 μL per mouse — to support retention at the injection site.
3. Anesthesia and laparotomy: Immunodeficient mice receive general anesthesia and analgesia; a small vertical incision is made in the upper abdomen, and the peritoneal cavity is opened by sharp dissection.
4. Exposure of the esophagus: The liver is gently elevated with a moist cotton swab, the stomach is lifted by traction on the greater curvature, and a micro-forceps is slid beneath the abdominal esophagus to lift and stretch the distal segment.
5. Intramural injection: A 30-gauge needle is inserted into the distal esophageal wall and tunneled proximally for roughly 3 mm before the cell–Matrigel suspension is slowly injected; a visible local bleb confirms correct intramural placement, while the rapidly solidifying Matrigel at body temperature prevents peritoneal spillage.
6. Closure and supportive care: The stomach is repositioned, the abdominal wall and skin are closed with a running 6-0 absorbable suture, and warmed fluids are given subcutaneously to prevent dehydration; mice are weighed regularly and observed for food intake and general status.
7. Tumor monitoring and endpoint analysis: Tumor development is followed by palpation, imaging where reporter-labeled cells are used, and body-weight tracking in vivo; at necropsy, primary tumors are measured and weighed, the esophageal wall is examined histologically for layer-by-layer invasion, and regional lymph nodes and peritoneum are screened for spread.

Fig 2. TE-1 orthotopic mouse model construction workflow.

Case Study-TE-1 Orthotopic Mouse Model Development

Alfa Cytology has carried out TE-1-based orthotopic modeling work within several preclinical research collaborations, covering model establishment and optimization, local invasion assessment, and therapeutic intervention studies against both parental and treatment-resistant backgrounds. These projects have produced internally consistent growth and histopathology readouts suitable for downstream efficacy interpretation, and case-specific details can be provided as programs progress.

Why Choose Alfa Cytology?

Orthotopic esophageal work demands surgical finesse and disciplined quality control in equal measure, and Alfa Cytology has organized its TE-1 service around exactly those two pillars.

• A senior surgical team experienced in the laparotomy-based intramural technique required for dependable TE-1 orthotopic tumor formation.
• Rigorous pre-study authentication of every TE-1 batch by STR profiling and mycoplasma testing.
• Clinically meaningful in-life readouts, including body weight and food-intake monitoring that mirror esophageal obstruction symptoms.
• Endpoint pathology that goes beyond tumor size to document wall-layer invasion, lymph node status, and peritoneal spread.
• Capability to pair parental TE-1 with its radioresistant derivative TE-1R for resistance and radiosensitizer studies.
• Preclinical-only scope: every workflow is designed, executed, and reported for research use, with no clinical-service contamination of your data package.

Contact Us

To bring the TE-1 orthotopic model into your esophageal cancer research, contact us and share your study objectives — our scientists will respond with a practical, cost-aware plan. Reach out today and let Alfa Cytology handle the modeling so you can focus on the discovery.

For research use only. Not intended for any clinical use.